Straits Times Index
3,251.09 -13.44 (-0.41%) Nikkei
38,357.76 +155.39 (+0.41%) Hang Seng
18,409.58 +95.72 (+0.52%) FTSE 100
8,354.05 +40.38 (+0.49%) Bitcoin USD
61,562.73 -1,175.01 (-1.87%) CMC Crypto 200
1,310.71 +16.03 (+1.24%)
TRACON Pharmaceuticals, Inc. (TCON)
After hours:
| Previous close | 1.8200 |
| Open | 1.8100 |
| Bid | 1.7200 x 100 |
| Ask | 1.8200 x 100 |
| Day's range | 1.7100 - 1.8392 |
| 52-week range | 1.5900 - 14.7400 |
| Volume | |
| Avg. volume | 259,216 |
| Market cap | 4.004M |
| Beta (5Y monthly) | 1.04 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -2.2000 |
| Earnings date | 14 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 37.50 |
GlobeNewswireTRACON to Report First Quarter 2024 Financial Results and Provide Corporate Update on May 14, 2024
SAN DIEGO, May 07, 2024 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development platform to advance its pipeline of novel targeted cancer therapeutics and to partner with other life science companies, announced today that it will report its first quarter 2024 financial and operating results after the close of U.S. financial markets on Tuesday, May 14, 2024. In addition, management
- GlobeNewswire
TRACON Pharmaceuticals Announces Reverse Stock Split
SAN DIEGO, April 08, 2024 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent Product Development Platform to advance its pipeline of novel targeted cancer therapeutics and to partner with other life science companies, today announced that, following stockholder approval at the special meeting of stockholders held on September 6, 2023 of a proposal authorizing the board of directors of the Company (the
- GlobeNewswire
TRACON Pharmaceuticals Provides Update on Ongoing ENVASARC Phase 2 Pivotal Trial Following Independent Data Monitoring Committee Recommendation to Continue the Trial as Planned
ENVASARC Trial is Fully Enrolled and Final Data are Expected in Third Quarter 2024 SAN DIEGO, April 03, 2024 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent Product Development Platform (PDP) to advance its pipeline of novel targeted cancer therapeutics and to partner with other life science companies, today announced the independent data monitoring committee (IDMC), following a review of ongoing sa
